Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 3Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Uterine Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Adenosquamous 1Adenocarcinoma 1

Interventions

pembrolizumab 8Paclitaxel 8Carboplatin 6Megestrol Acetate 4niraparib 3Cisplatin 3tislelizumab 2technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2rucaparib 2olaparib 2iso-sulfan blue 2copanlisib 2Taxes 2Surveys and Questionnaires 2Nivolumab 2Lymph Node Excision 2Indocyanine Green 2Fulvestrant 2Filgrastim 2Doxorubicin 2Docetaxel 2tremelimumab 1spartalizumab 1sonidegib 1ribociclib 1rebastinib 1pemigatinib 1nicotinamide-beta-riboside 1lenvatinib 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Endometrial Neoplasms × Hysterectomy × Clear all
NCT03694834 2023-11-28

Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer

UNC Lineberger Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
3 enrolled
Gynecologic

Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡